A Multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory/relapsed aggressive non-Hodgkin's lymphoma

被引：0

作者：

Sym, Sun Jin ^{[1
]}

Kang, Hye Jin ^{[2
]}

Nam, Seung-Hyun ^{[3
]}

Kim, Hoyoung ^{[4
]}

Kim, Seok Jin ^{[5
]}

Eom, Hyeon Seok ^{[6
]}

Kim, Won Seog ^{[7
]}

Suh, Cheolwon ^{[1
]}

机构：

[1] Asan Med Ctr, Dept Internal Med, Seoul, South Korea

[2] Korea Inst Radiol & Med Sci, Dept Internal Med, Seoul, South Korea

[3] Seoul Vet Hosp, Dept Internal Med, Seoul, South Korea

[4] Wonju Christian Hosp, Dept Internal Med, Wonju, South Korea

[5] Korea Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[6] Clin Ctr Specific Organs Canc, Natl Canc Ctr, Seoul, South Korea

[7] Samsung Med Ctr, Dept Med, Seoul, South Korea

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.3446.3446

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3446

引用

页码：1010A / 1010A

页数：1

共 50 条

[1] A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma
Sym, Sun Jin
Lee, Dae Ho
Kang, Hye Jin
Nam, Seung Hyun
Kim, Ho Young
Kim, Seok Jin
Eom, Hyeon Seok
Kim, Won Seog
Suh, Cheolwon
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) : 27 - 33
[2] A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma
Sun Jin Sym
Dae Ho Lee
Hye Jin Kang
Seung Hyun Nam
Ho Young Kim
Seok Jin Kim
Hyeon Seok Eom
Won Seog Kim
Cheolwon Suh
Cancer Chemotherapy and Pharmacology, 2009, 64 : 27 - 33
[3] A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin’s lymphoma
Young-Woong Won
Hyewon Lee
Hyeon-Seok Eom
Jin Seok Kim
Cheolwon Suh
Dok Hyun Yoon
Jung Yong Hong
Hye Jin Kang
Jae Hoon Lee
Won Seog Kim
Seok Jin Kim
Won-Sik Lee
Myung Hee Chang
Young Rok Do
Jun Ho Yi
Inho Kim
Jong-Ho Won
Kyoungha Kim
Sung Yong Oh
Jae-Cheol Jo
Annals of Hematology, 2020, 99 : 255 - 264
[4] A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma
Won, Young-Woong
Lee, Hyewon
Eom, Hyeon-Seok
Kim, Jin Seok
Suh, Cheolwon
Yoon, Dok Hyun
Hong, Jung Yong
Kang, Hye Jin
Lee, Jae Hoon
Kim, Won Seog
Kim, Seok Jin
Lee, Won-Sik
Chang, Myung Hee
Do, Young Rok
Yi, Jun Ho
Kim, Inho
Won, Jong-Ho
Kim, Kyoungha
Oh, Sung Yong
Jo, Jae-Cheol
ANNALS OF HEMATOLOGY, 2020, 99 (02) : 255 - 264
[5] A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with refractory/relapsed aggressive non-Hodgkins lymphoma: Preliminary results
Sym, S. J.
Kang, H. J.
Nam, S. H.
Kim, H. Y.
Kim, S. J.
Eom, H. S.
Kim, W. S.
Suh, C. W.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 268 - 269
[6] High-dose ifosfamide and etoposide infusion plus methylprednisolone for refractory or relapsed aggressive non-Hodgkin's lymphoma
Salar, A
Martino, R
Altés, A
Sureda, A
Brunet, S
Sierra, J
HAEMATOLOGICA, 2000, 85 (02) : 217 - 219
[7] Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma
Machover, D
Delmas-Marsalet, B
Misra, SC
Gumus, Y
Goldschmidt, E
Schilf, A
Frénoy, N
Emile, JF
Debuire, B
Guettier, C
Farrokhi, P
Boulefdaoui, B
Norol, F
Parquet, N
Ulusakarya, A
Jasmin, C
ANNALS OF ONCOLOGY, 2001, 12 (10) : 1439 - 1443
[8] Cologne high-dose sequential chemotherapy in relapsed and refractory aggressive non-Hodgkin's lymphoma results of multicenter phase II study
Josting, A
Sieniawski, M
Staak, J
Diehl, V
Engert, A
ANNALS OF ONCOLOGY, 2005, 16 : 183 - 183
[9] A phase II trial of dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab as salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma.
Mey, UJM
Strehl, JW
Orlopp, KS
Flieger, D
Birkmann, J
Ho, A
Kaiser, U
Neubauer, A
Glasmacher, AG
Schmidt-Wolf, IGH
BLOOD, 2004, 104 (11) : 238B - 238B
[10] Dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab as salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma: Updated results of a multicenter phase II trial.
Mey, UJM
Flieger, D
Birkmann, J
Neubauer, A
Ho, AD
Kaiser, U
Wilhelm, M
Haarmann, G
Hahn, C
Strehl, JW
Glasmacher, AG
Schmidt-Wolf, IGH
BLOOD, 2003, 102 (11) : 300B - 301B

← 1 2 3 4 5 →